{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:31:56Z","timestamp":1791325916170,"version":"4.3.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.lungcan.2014.05.003","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T17:06:43Z","timestamp":1400000803000},"page":"420-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer"],"prefix":"10.1016","volume":"85","clinical-trial-number":[{"clinical-trial-number":"nct00682981","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Corey J.","family":"Langer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Johnetta","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Pajkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Somfay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Zatloukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kazarnowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi M.","family":"Moezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall T.","family":"Schreeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Schnyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Ao-Baslock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh K.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2014.05.003_bib0005","unstructured":"American Cancer Institute. Cancer Facts & Figures 2012. 2012. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-031941.pdf. Accessed December 4, 2013."},{"key":"10.1016\/j.lungcan.2014.05.003_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer Statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0015","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0025","series-title":"NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 1.2014","author":"National Comprehensive Cancer Network","year":"2013"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0030","series-title":"NICE Clinical Guideline 121. Lung cancer. The diagnosis and treatment of lung cancer","author":"National Institute for Health Clinical Excellence","year":"2011"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2014.05.003_bib0035","doi-asserted-by":"crossref","first-page":"v120","DOI":"10.1093\/annonc\/mdq172","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Sorensen","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2007.14.3461","article-title":"Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0045","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0050","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1200\/JCO.2006.07.7016","article-title":"Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer","volume":"24","author":"Socinski","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0060","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0065","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-003-0763-9","article-title":"Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment","volume":"442","author":"Fokkema","year":"2003","journal-title":"Virchows Arch"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas","volume":"177","author":"Jiang","year":"1995","journal-title":"J Pathol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0075","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ijc.10096","article-title":"Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines","volume":"97","author":"Sartorius","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0080","first-page":"212","article-title":"Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer","volume":"2","author":"Takayama","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000227526","article-title":"Immunohistochemical detection of Bcl-2 protein in small cell carcinomas","volume":"53","author":"Yan","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-010-1265-5","article-title":"A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies","volume":"66","author":"Paik","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0095","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/jco.2009.27.15_suppl.3576","article-title":"A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)","volume":"27","author":"Chiappori","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/bjc.2012.21","article-title":"A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer","volume":"106","author":"Chiappori","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.bjc.6604480","article-title":"Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer","volume":"99","author":"Baka","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0110","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)","volume":"2","author":"Pandya","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0120","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","article-title":"Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial","volume":"29","author":"Spigel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/JTO.0b013e31820a0ea6","article-title":"Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer","volume":"6","author":"Ready","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0130","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/JTO.0b013e3181e8f4dc","article-title":"Phase I\/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer","volume":"5","author":"Heist","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0135","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","article-title":"A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0140","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JTO.0000000000000027","article-title":"Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1\/2 trial in relapsed non-small-cell lung cancer","volume":"9","author":"Chiappori","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0150","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1158\/1078-0432.CCR-08-0111","article-title":"Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer","volume":"14","author":"Micha","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2014.05.003_bib0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1593\/neo.101524","article-title":"Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer","volume":"13","author":"Dean","year":"2011","journal-title":"Neoplasia"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T10:41:20Z","timestamp":1648982480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214002128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0169500214002128"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}